Several other research firms have also recently commented on MRK. Commerzbank set a €100.00 ($116.28) price objective on Merck KGaA and gave the company a buy rating in a research report on Wednesday. JPMorgan Chase & Co. reissued a neutral rating on shares of Merck KGaA in a report on Wednesday. UBS Group set a €115.00 ($133.72) target price on Merck KGaA and gave the company a buy rating in a report on Wednesday. Goldman Sachs Group set a €92.00 ($106.98) target price on Merck KGaA and gave the company a neutral rating in a report on Wednesday. Finally, Barclays set a €70.00 ($81.40) target price on Merck KGaA and gave the company a sell rating in a report on Friday, August 24th. One equities research analyst has rated the stock with a sell rating, twelve have issued a hold rating and nine have given a buy rating to the company’s stock. Merck KGaA has a consensus rating of Hold and a consensus price target of €98.76 ($114.84).
Merck KGaA stock opened at €93.72 ($108.98) on Wednesday. Merck KGaA has a one year low of €76.60 ($89.07) and a one year high of €115.00 ($133.72).
MERCK Kommanditgesellschaft auf Aktien, a science and technology company, operates in the healthcare, life science, and performance materials sectors worldwide. The company offers prescription medicines to treat infertility, growth hormone deficiencies, type 2 diabetes, cardiovascular and thyroid diseases, multiple sclerosis, colorectal cancer, as well as carcinoma of the head and neck; diagnostics and prescription drugs for allergen immunotherapy; and fertility treatments.
Featured Article: Put Option
Receive News & Ratings for Merck KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck KGaA and related companies with MarketBeat.com's FREE daily email newsletter.